Tag: Leqembi
The drug companies want $26,500 per year for the newest Alzheimer’s drug; negotiations might take it to $20,000. The potential for full Food and Drug Administration approval of the new Biogen-Esai Alzheimer’s drug (Leqembi) means that Medicare may make the drug available to beneficiaries. The $26,500 annual price tag associated with Leqembi will wreak havoc wit…
How to alleviate ravages of the disease without bankrupting individuals or Medicare program? The Food and Drug Administration recently granted fast-track approval to a new Alzheimer’s drug designed to slow the rate of cognitive decline for individuals in the early stages of the disease. The drug, which will be sold under the brand name Leqembi,…
